The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Lung cancer highlights from ASCO 2025
João Alessi, MD, Dana-Farber Cancer Institute, Boston, MA, and Alessandro Di Federico, MD, Dana-Farber Cancer Institute, Boston, MA, discuss key findings in lung cancer management from ASCO 2025. They highlight the practice-changing results of the DeLLphi-304 trial (NCT05740566) showing tarlatamab’s impressive efficacy in second-line small cell lung cancer, with over 13 months median overall survival, and discuss promising results from the OptiTROP-Lung03 trial (NCT05631262) testing sacituzumab tirumotecan for EGFR-mutant non-small cell lung cancer patients. The conversation also covers updated results from the CheckMate 816 trial (NCT02998528) on neoadjuvant chemo-immunotherapy and the surprising success of the ALNEO trial in ALK-rearranged resectable stage III non-small cell lung cancer. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
